Vascular dementia (VaD) results from cerebrovascular disease affecting brain parenchyma, leading to cognitive impairment through multiple mechanisms including strategic infarcts, white matter lesions, and hypoperfusion. The neuronal populations affected in VaD differ from those primarily targeted in Alzheimer's disease, though mixed pathology is common. Understanding which neurons are vulnerable in VaD provides insights into disease mechanisms and therapeutic targets.
| Property |
Value |
| Category |
Cerebrovascular neurodegeneration |
| Species |
Human |
| Brain Regions |
Subcortical white matter, hippocampus, cortex, basal ganglia |
| Neurotransmitters |
Multiple (glutamate, GABA, acetylcholine, dopamine) |
| Risk Factors |
Hypertension, diabetes, atherosclerosis, atrial fibrillation |
Strategic infarcts in key cognitive areas produce stepwise decline:
Hippocampal infarcts
- CA1 sector: Vulnerability to hypoperfusion
- Subiculum: Memory circuit disruption
- Entorhinal cortex: Gateway dysfunction
Thalamic infarcts
- Anterior thalamic nuclei: Memory circuits
- Mediodorsal thalamus: Executive function
- Pulvinar: Attention and visual processing
Basal ganglia infarcts
- Nucleus basalis of Meynert: Cholinergic dysfunction
- Caudate: Executive dysfunction
- Putamen: Motor and cognitive integration
Chronic small vessel disease affects:
White matter lesions
- Periventricular hyperintensities
- Deep white matter hyperintensities
- Disconnection of frontostriatal circuits
Vulnerable neurons
- Layer III cortical pyramidal neurons
- Striatal medium spiny neurons
- Thalamic relay neurons
¶ Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Hereditary small vessel disease:
- Gene: NOTCH3 mutations
- Target cells: Vascular smooth muscle cells
- Neuronal effects: Chronic hypoperfusion, white matter damage
The basal forebrain cholinergic system is severely affected in VaD:
Nucleus Basalis of Meynert (NBM)
- Cholinergic neuron loss (40-60%)
- Correlation with white matter hyperintensity load
- Contributes to attention and memory deficits
Medial septum
- Hippocampal cholinergic input disruption
- Memory impairment mechanisms
Layer III neurons
- Long-range corticocortical projections
- Vulnerable to hypoperfusion
- Executive dysfunction correlation
Layer V neurons
- Subcortical projections
- Motor and cognitive integration
While not neurons, oligodendrocyte loss is critical:
- Myelin degeneration
- Saltatory conduction impairment
- Network disconnection
Excitotoxicity
- Glutamate release during ischemia
- NMDA receptor overactivation
- Calcium influx and cell death
Oxidative stress
- Reactive oxygen species generation
- Mitochondrial dysfunction
- Lipid peroxidation
- Pericyte dysfunction
- Endothelial damage
- Plasma protein extravasation
- Inflammatory cell infiltration
Microglial activation
- Pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6)
- Phagocytosis of damaged neurons
- Chronic neuroinflammation
Perivascular inflammation
- Monocyte infiltration
- T-cell involvement
Executive dysfunction
- Planning and organization
- Working memory impairment
- Set-shifting deficits
Memory impairment
- Retrieval deficits
- Less encoding impairment than AD
- Temporal context preserved
Attention deficits
- Reduced vigilance
- Impaired divided attention
- Slowed information processing
- Gait disturbance
- Postural instability
- Urinary incontinence
- Pseudobulbar affect
- Depression (most common)
- Apathy
- Emotional lability
- Psychosis (less common than AD)
MRI findings
- White matter hyperintensities (Fazekas scale)
- Lacunar infarcts
- Hippocampal atrophy (milder than AD)
- Microbleeds (CMB)
CT findings
- White matter low attenuation
- Cortical atrophy
- Strategic infarcts
CSF markers
- Elevated tau (less than AD)
- Reduced Aβ42 (in mixed pathology)
- Neurofilament light chain (NFL) - axonal damage
Blood markers
- Neurofilament light chain
- GFAP (astrocytic activation)
Blood pressure control
- Target: <130/80 mmHg
- ACE inhibitors, ARBs recommended
Antiplatelet therapy
- Aspirin, clopidogrel
- Caution with cerebral microbleeds
Statins
- LDL target: <70 mg/dL
- Pleiotropic effects
Cholinesterase inhibitors
- Donepezil, rivastigmine, galantamine
- Modest benefit in VaD
- Particularly useful with mixed AD/VaD
Memantine
- NMDA receptor modulation
- May improve cognition and function
- Anti-amyloid therapies in mixed pathology
- Anti-tau approaches
- Neuroprotective agents
- Stem cell therapies
- Vascular dementia: Neuronal vulnerability and pathophysiology (2020)
- White matter lesions and cognitive decline (2019)
- Cholinergic dysfunction in vascular dementia (2018)
- Binswanger disease: Clinical and pathological features (2021)
- Executive dysfunction in subcortical VaD (2017)
- CADASIL: NOTCH3 and neuronal dysfunction (2019)
- Mixed dementia: AD and VaD overlap (2020)
- Therapeutic approaches to vascular cognitive impairment (2021)
- Blood-brain barrier in vascular dementia (2018)
- Neuroimaging biomarkers for VaD diagnosis (2022)